3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Thymoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
9
Gemcitabine
5
Cisplatin
5
Nivolumab
3
Drug Therapy
3
budigalimab
2
Paclitaxel
2
Injections
2
Docetaxel
2
Carboplatin
2
zenocutuzumab
1
venetoclax
1
tislelizumab
1
spartalizumab
1
seribantumab
1
saracatinib
1
rovalpituzumab tesirine
1
pertuzumab
1
pemigatinib
1
niraparib
1
nilotinib
1
margetuximab
1
lenvatinib
1
futibatinib
1
fludarabine
1
entrectinib
1
durvalumab
1
crenigacestat
1
cediranib
1
bemarituzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
anetumab ravtansine
×
Breast
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled